These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34687551)

  • 1. Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
    Naagaard MD; Chang R; Någård M; Tang W; Boulton DW
    Br J Clin Pharmacol; 2022 Feb; 88(4):1942-1946. PubMed ID: 34687551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity.
    Okada J; Yamada E; Saito T; Yokoo H; Osaki A; Shimoda Y; Ozawa A; Nakajima Y; Pessin JE; Okada S; Yamada M
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31979355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
    Kasichayanula S; Liu X; Griffen SC; Lacreta FP; Boulton DW
    Diabetes Obes Metab; 2013 Mar; 15(3):280-3. PubMed ID: 23061428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes.
    Jo H; Pilla Reddy V; Parkinson J; Boulton DW; Tang W
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):108-118. PubMed ID: 33439535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of dapagliflozin on colon cancer cell [Rapid Communication].
    Saito T; Okada S; Yamada E; Shimoda Y; Osaki A; Tagaya Y; Shibusawa R; Okada J; Yamada M
    Endocr J; 2015; 62(12):1133-7. PubMed ID: 26522271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure.
    Marshall JC; Liang Y; Sahasrabudhe V; Tensfeldt T; Fediuk DJ; Zhou S; Krishna R; Dawra VK; Wood LS; Sweeney K
    J Clin Pharmacol; 2021 Sep; 61(9):1220-1231. PubMed ID: 33813736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.
    He X; Li Y; Ma Y; Fu Y; Xun X; Cui Y; Dong Z
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
    Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
    Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
    Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
    Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
    Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
    Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
    Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin: A Sodium Glucose Cotransporter 2 Inhibitor for the Treatment of Diabetes Mellitus.
    Davis PN; Ndefo UA; Oliver A
    J Pharm Pract; 2016 Apr; 29(2):165-71. PubMed ID: 25609661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
    Demaris KM; White JR
    Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions.
    Pattanawongsa A; Chau N; Rowland A; Miners JO
    Drug Metab Dispos; 2015 Oct; 43(10):1468-76. PubMed ID: 26180128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
    Komoroski B; Vachharajani N; Feng Y; Li L; Kornhauser D; Pfister M
    Clin Pharmacol Ther; 2009 May; 85(5):513-9. PubMed ID: 19129749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
    Melin J; Tang W; Rekić D; Hamrén B; Penland RC; Boulton DW; Parkinson J
    J Clin Pharmacol; 2022 Oct; 62(10):1227-1235. PubMed ID: 35403243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Meng W; Ellsworth BA; Nirschl AA; McCann PJ; Patel M; Girotra RN; Wu G; Sher PM; Morrison EP; Biller SA; Zahler R; Deshpande PP; Pullockaran A; Hagan DL; Morgan N; Taylor JR; Obermeier MT; Humphreys WG; Khanna A; Discenza L; Robertson JG; Wang A; Han S; Wetterau JR; Janovitz EB; Flint OP; Whaley JM; Washburn WN
    J Med Chem; 2008 Mar; 51(5):1145-9. PubMed ID: 18260618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.